In the study by Alraouji et al., the authors investigated the effects of tocilizumab, an IL-6 receptor alpha agonistic antibody, on IL-8 production and the proangiogenic potential of triple-negative breast cancer cells [89]. The gene discussed is CXCL8; the disease is triple-negative breast carcinoma.